Exposure to Amphetamines Leads to Development of Amphetamine Type Stimulants Associated Cardiomyopathy (ATSAC).
With rapidly rising prevalence of exposure to Amphetamine Type Stimulants (ATS), novel insights into cardiotoxic effects of this substance are being presented in the literature and remarkably ATS Associated Cardiomyopathy (ATSAC) is emerging as a novel cardiovascular condition with its distinctive pathogenesis, risk factors, clinical features and prognosis. A comprehensive systematic review was performed to explore and analyze the current evidence on the association between ATS exposure and development of cardiomyopathy, biological mechanisms involved in pathogenesis of ATSAC, risk factors, clinical features and course of patients with ATSAC. Several animal studies, case reports, case series and case-control studies support the association between ATS exposure and ATSAC. Oxidative stress, accelerated apoptosis, increased p53 activity, cardiomyocyte necrosis, perfusion defects, fatty acid toxicity, altered gene expression, abnormal cardiac protein synthesis and function in addition to defects in intracellular calcium hemostasis present themselves as likely mechanisms of cardiotoxicity in ATSAC. Majority of patients with ATSAC were found to be male, young and presented late with severe dilated cardiomyopathy. Female ATS users predominantly develop Takotsubo type of ATSAC and in particular its atypical basal variant. Overall, cessation of ATS exposure seems to be associated with some degree of reversibility and recovery in ATSAC sufferers.
Department of Cardiology, St Vincent's Hospital (Melbourne), PO Box 2900, Fitzroy, VIC, 3065, Australia. Mahsa.JAFARIGIV@svha.org.au.
Mahsa
M
Jafari Giv
D000328:Adult; D019969:Amphetamine-Related Disorders / Q000150:complications*; D000662:Amphetamines / Q000009:adverse effects*; D000818:Animals; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000175:diagnosis / Q000378:metabolism / Q000503:physiopathology; D066126:Cardiotoxicity; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D000697:Central Nervous System Stimulants / Q000009:adverse effects*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012307:Risk Factors; D055815:Young Adult
D000662:Amphetamines; D000697:Central Nervous System Stimulants
Amphetamine-related disorders; Cardiomyopathy; Cardiotoxicity; Cardiovascular toxicity; Methamphetamine; Takotsubo cardiomyopathy